178 related articles for article (PubMed ID: 22616398)
1. Which orphans will find a home? The rule of rescue in resource allocation for rare diseases.
Largent EA; Pearson SD
Hastings Cent Rep; 2012; 42(1):27-34. PubMed ID: 22616398
[No Abstract] [Full Text] [Related]
2. How should we model rare disease allocation decisions?
London AJ
Hastings Cent Rep; 2012; 42(1):3. PubMed ID: 22616383
[No Abstract] [Full Text] [Related]
3. Two dreams.
Hastings Cent Rep; 2012; 42(1):2. PubMed ID: 22616382
[No Abstract] [Full Text] [Related]
4. The many vs. the few.
Loewenstein G
Hastings Cent Rep; 2012; 42(5):7-8; author reply 8-9. PubMed ID: 23050293
[No Abstract] [Full Text] [Related]
5. The many vs. the few.
Wells RJ
Hastings Cent Rep; 2012; 42(5):7; author reply 8-9. PubMed ID: 23050292
[No Abstract] [Full Text] [Related]
6. The many vs. the few.
Menzel PT
Hastings Cent Rep; 2012; 42(5):5-6; author reply 8-9. PubMed ID: 23050290
[No Abstract] [Full Text] [Related]
7. The many vs. the few.
McCabe C
Hastings Cent Rep; 2012; 42(5):6-7; author reply 8-9. PubMed ID: 23050291
[No Abstract] [Full Text] [Related]
8. The many vs. the few.
Zallen DT
Hastings Cent Rep; 2012; 42(5):4-5; author reply 8-9. PubMed ID: 22976402
[No Abstract] [Full Text] [Related]
9. Improving fairness in coverage decisions: insights from the Harvard Community Health Plan's LORAN Commission Report.
Paris JJ
Am J Bioeth; 2004; 4(3):103-4; discussion W40-2. PubMed ID: 16192160
[No Abstract] [Full Text] [Related]
10. Are your insurance premiums my problem?
Groenhout R
APA Newsl Philos Med; 2000; 00(1):137-43. PubMed ID: 15470791
[No Abstract] [Full Text] [Related]
11. Rationing of drugs for rare diseases.
Hughes D
Pharmacoeconomics; 2006; 24(4):315-6. PubMed ID: 16605277
[No Abstract] [Full Text] [Related]
12. Clinical justice guiding medical allocations.
Rhodes R
Am J Bioeth; 2004; 4(3):116-9; discussion W40-2. PubMed ID: 16192168
[No Abstract] [Full Text] [Related]
13. The ethical quality report card: confronting rationing.
Strosberg MA
Am J Bioeth; 2004; 4(3):114-5; discussion W40-2. PubMed ID: 16192166
[No Abstract] [Full Text] [Related]
14. [Authorization and reimbursement of orphan drugs in an international comparison].
Roll K; Stargardt T; Schreyögg J
Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
[TBL] [Abstract][Full Text] [Related]
15. Dodging the rules, ruling the dodgers.
Morreim H
Am J Bioeth; 2012; 12(3):1-3. PubMed ID: 22416739
[No Abstract] [Full Text] [Related]
16. Orphan drugs revisited.
McCabe C; Tsuchiya A; Claxton K; Raftery J
QJM; 2006 May; 99(5):341-5; discussion 350-1. PubMed ID: 16504983
[No Abstract] [Full Text] [Related]
17. Evaluating and Valuing Drugs for Rare Conditions: No Easy Answers.
Ollendorf DA; Chapman RH; Pearson SD
Value Health; 2018 May; 21(5):547-552. PubMed ID: 29753351
[TBL] [Abstract][Full Text] [Related]
18. Personal reflections of a patient representative in an appraisal committee.
Smit C
Patient; 2015 Feb; 8(1):5-10. PubMed ID: 25256116
[No Abstract] [Full Text] [Related]
19. [Shift of focus in the financing of Hungarian drugs. Reimbursement for orphan drugs for treating rare diseases: financing of enzyme replacement therapy in Hungary].
Szegedi M; Molnár MJ; Boncz I; Kosztolányi G
Orv Hetil; 2014 Nov; 155(44):1735-41. PubMed ID: 25344850
[TBL] [Abstract][Full Text] [Related]
20. Competing for public funding of medicines to treat rare disorders in New Zealand.
Crausaz S
Bull World Health Organ; 2015 Feb; 93(2):67. PubMed ID: 25883396
[No Abstract] [Full Text] [Related]
[Next] [New Search]
